Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Egerer

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myelomaK Neben, T Moehler, G Egerer, et al.
Zentralblatt Fur Bakteriologie : International Journal of Medical Microbiology|April 9, 1998
Increased risk of catheter colonization and catheter-related infections in severe immunocompromized patients with multiple myeloma undergoing high-dose glucocorticoid treatmentH Goldschmidt, H J Salwender, U Hahn, et al.
Bone Marrow Transplantation|October 9, 2002
Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantationG Egerer, H Goldschmidt, M Hensel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 11, 2001
Outpatient treatment of multiple myeloma with a combination of vincristine, Adriamycin and dexamethasoneG Egerer, U Hegenbart, H Salwender, et al.
Bone Marrow Transplantation|January 10, 2006
Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trialC Harter, B Schulze, H Goldschmidt, et al.
Annals of Hematology|August 14, 2015
The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphomaM Madle, I Krämer, N Lehners, et al.
Wiener Medizinische Wochenschrift (1946)|February 27, 1999
[Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration]M Karthaus, T Südhoff, K Fenchel, et al.
British Journal of Cancer|September 14, 2006
Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgeryA Zahlten-Hinguranage, H Goldschmidt, F W Cremer, et al.
Die Rehabilitation|May 1, 1997
[Rehabilitation of patients with alcoholic liver cirrhosis after orthotopic liver transplantation: a 7-year follow-up]U H Reeck, G Egerer, G Otto, et al.
Bone Marrow Transplantation|November 18, 1998
Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cellsS Hohaus, H Martin, B Wassmann, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2001
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myelomaK Neben, T Moehler, G Egerer, et al.
Zentralblatt Fur Bakteriologie : International Journal of Medical Microbiology|April 9, 1998
Increased risk of catheter colonization and catheter-related infections in severe immunocompromized patients with multiple myeloma undergoing high-dose glucocorticoid treatmentH Goldschmidt, H J Salwender, U Hahn, et al.
Bone Marrow Transplantation|October 9, 2002
Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantationG Egerer, H Goldschmidt, M Hensel, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 11, 2001
Outpatient treatment of multiple myeloma with a combination of vincristine, Adriamycin and dexamethasoneG Egerer, U Hegenbart, H Salwender, et al.
Bone Marrow Transplantation|January 10, 2006
Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trialC Harter, B Schulze, H Goldschmidt, et al.
Annals of Hematology|August 14, 2015
The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphomaM Madle, I Krämer, N Lehners, et al.
Wiener Medizinische Wochenschrift (1946)|February 27, 1999
[Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration]M Karthaus, T Südhoff, K Fenchel, et al.
British Journal of Cancer|September 14, 2006
Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgeryA Zahlten-Hinguranage, H Goldschmidt, F W Cremer, et al.
Die Rehabilitation|May 1, 1997
[Rehabilitation of patients with alcoholic liver cirrhosis after orthotopic liver transplantation: a 7-year follow-up]U H Reeck, G Egerer, G Otto, et al.
Bone Marrow Transplantation|November 18, 1998
Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cellsS Hohaus, H Martin, B Wassmann, et al.
Pageof 8